

EP272: RAAS-inhibition and diagnostic challenges in severe primary hyperaldosteronism

Introduction

- Accurate diagnosis in primary hyperaldosteronism is essential for adequate causative treatment¹
- RAAS-affecting antihypertensives may interfere with diagnostic procedures, possibly leading to misclassification of disease¹
- Withdrawal of RAAS-inhibition may not be possible in patients with severe hyperaldosteronemia due to treatment refractory hypertension and hypokalemia
- AIM: to report on the diagnostic and curative outcomes in a case of a patient with severe hyperaldosteronism where RAAS-inhibition could not be safely withdrawn

Case history

- 37 year old Caucasian male
- Referred for primary hyperaldosteronism, no causative diagnosis
- Current medication: spironolactone 200mg, barnidipine 20mg, doxazosine 12mg, metoprolol 25 mg, potassium chloride 100 mmol
- Withdrawal of RAAS-interfering medication led to hypokalemic hypertensive crisis and repeated emergency unit admittance
- Symptomatology: muscle weakness. Agressive and restless. Reduced libido
- Physical: BP 150/110 mmHg, BMI 36,3 kg/m², Adiposity and gynaecomastia
- Lab: Sodium 144 mmol/L, potassium 3.9 mmol/L.
 (No medication) Renin 3.8 mU/L (ref 5.3 99)
 Aldo 3620 pmol/L (ref 100 1200) (ARR 952 pmol/mU)


Clinical course

- Indication for selective Adrenal Vein Sampling (AVS)
- Medication adjusted to:
 - Spironolactone tapered, potassium chloride titrated
 - Hydralazine, verapamil and doxazosine for hypertension
- Two weeks after discontinuing spironolactone >> emergency room :
 - Complaints: dizzy, blurry vision, headache
 - Hypertensive :185/110 mmHg
 - Medication: hydralazine 80mg, doxazosine 16mg, verapamol 240mg, potassium 250 mmol
 - Retinal examination: grade II hypertensive retinopathy
 - → Enalapril added while monitoring renin concentration (*Panel*)
- AVS succesfully performed while taking enalapril 40mg daily
 - Evident right sided origin of aldosteron hypersecretion
 - Spironolactone reinitiated while waiting for surgery (400mg/day)
- Succesful right side adrenalectomy
 - Currently **normotensive** with lisinopril monotherapy
 - Aldo <100 pmol/L

Conclusions

- Even in very severe primary hyperaldosteronism, RAAS-interfering medication should be withdrawn to allow for accurate diagnostic testing and possible curative treatment.
- Very high doses of potassium replacement and mineralocorticoid antagonists may be required to treat the severe phenotype
- If RAAS-interfering medication cannot be withdrawn, then renin (activity) should be measured; diagnostic procedures can be interpreted reliably in case of persistently suppressed renin concentrations/activity.

Imaging **The state of the sta





References

1) Rossi et al., Hypertension 2014

Acknowledgments

We would like to thank the patient for his kind permission to present his case history



Contact: M.F. Nijhoff@lumc.nl



